AdvisorNet Financial Inc Purchases Shares of 1,885 Twist Bioscience Co. (NASDAQ:TWST)

AdvisorNet Financial Inc purchased a new stake in shares of Twist Bioscience Co. (NASDAQ:TWSTGet Rating) in the second quarter, HoldingsChannel reports. The institutional investor purchased 1,885 shares of the company’s stock, valued at approximately $66,000.

A number of other large investors have also made changes to their positions in TWST. ARK Investment Management LLC grew its stake in shares of Twist Bioscience by 39.7% during the 1st quarter. ARK Investment Management LLC now owns 5,264,255 shares of the company’s stock valued at $259,949,000 after acquiring an additional 1,497,052 shares during the period. Capital World Investors grew its stake in shares of Twist Bioscience by 6.0% during the 1st quarter. Capital World Investors now owns 4,795,848 shares of the company’s stock valued at $236,819,000 after acquiring an additional 273,148 shares during the period. Vanguard Group Inc. grew its stake in shares of Twist Bioscience by 10.8% during the 1st quarter. Vanguard Group Inc. now owns 4,791,074 shares of the company’s stock valued at $236,584,000 after acquiring an additional 467,466 shares during the period. BlackRock Inc. grew its stake in shares of Twist Bioscience by 8.3% during the 1st quarter. BlackRock Inc. now owns 4,692,119 shares of the company’s stock valued at $231,696,000 after acquiring an additional 358,217 shares during the period. Finally, State Street Corp grew its stake in shares of Twist Bioscience by 54.9% during the 1st quarter. State Street Corp now owns 2,480,409 shares of the company’s stock valued at $122,483,000 after acquiring an additional 879,566 shares during the period.

Insider Transactions at Twist Bioscience

In other news, insider William Banyai sold 1,275 shares of the company’s stock in a transaction that occurred on Monday, August 22nd. The stock was sold at an average price of $41.94, for a total transaction of $53,473.50. Following the sale, the insider now directly owns 256,779 shares of the company’s stock, valued at approximately $10,769,311.26. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, insider William Banyai sold 1,275 shares of the company’s stock in a transaction that occurred on Monday, August 22nd. The stock was sold at an average price of $41.94, for a total transaction of $53,473.50. Following the sale, the insider now directly owns 256,779 shares of the company’s stock, valued at approximately $10,769,311.26. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO James M. Thorburn sold 9,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 17th. The stock was sold at an average price of $48.51, for a total value of $436,590.00. Following the sale, the chief financial officer now directly owns 38,831 shares in the company, valued at $1,883,691.81. The disclosure for this sale can be found here. Insiders have sold 19,485 shares of company stock valued at $836,768 in the last ninety days. Corporate insiders own 3.10% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on TWST shares. Barclays boosted their price objective on Twist Bioscience from $45.00 to $55.00 and gave the company an “overweight” rating in a research note on Monday, August 8th. SVB Leerink boosted their price objective on Twist Bioscience from $45.00 to $50.00 and gave the company a “market perform” rating in a research note on Monday, August 8th. Finally, Robert W. Baird boosted their price target on Twist Bioscience from $43.00 to $56.00 in a report on Monday, August 8th.

Twist Bioscience Trading Down 7.5 %

NASDAQ TWST opened at $33.64 on Friday. The stock’s 50 day moving average is $43.58 and its 200 day moving average is $40.21. Twist Bioscience Co. has a 12 month low of $25.07 and a 12 month high of $139.99. The stock has a market cap of $1.90 billion, a PE ratio of -8.49 and a beta of 1.21.

Twist Bioscience (NASDAQ:TWSTGet Rating) last posted its quarterly earnings results on Friday, August 5th. The company reported ($1.08) EPS for the quarter, topping analysts’ consensus estimates of ($1.30) by $0.22. Twist Bioscience had a negative return on equity of 29.61% and a negative net margin of 112.91%. The company had revenue of $56.10 million for the quarter, compared to analysts’ expectations of $52.06 million. During the same period in the previous year, the firm earned ($0.82) EPS. The firm’s revenue was up 60.3% compared to the same quarter last year. On average, analysts forecast that Twist Bioscience Co. will post -4.53 EPS for the current fiscal year.

About Twist Bioscience

(Get Rating)

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.

Featured Articles

Want to see what other hedge funds are holding TWST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Twist Bioscience Co. (NASDAQ:TWSTGet Rating).

Institutional Ownership by Quarter for Twist Bioscience (NASDAQ:TWST)

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.